# Safety, Efficacy, and Biomarker Analysis of Pyrotinib in Combination with Capecitabine in HER2-Positive Metastatic Breast Cancer Patients: A Phase I Clinical Trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/safety-efficacy-and-biomarker-analysis-of-pyrotinib-in-combination-with/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Qiao Li,Xiuwen Guan,Shanshan Chen,Zongbi Yi,Bo Lan,Puyuan Xing,Ying Fan,Jiayu Wang,Yang Luo,Peng Yuan,Ruigang Cai,Pin Zhang,Qing Li,Dafang Zhong,Yifan Zhang,Jianjun Zou,Xiaoyu Zhu,Fei Ma,Binghe Xu |
| Citations | 93 |
| DOI | 10.1158/1078-0432.ccr-18-4173 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2947067095 |
| PMID | 31138588 |
| Type | article |
| Year | 2019 |

## Paper authors

- [Puyuan Xing](https://scholariq.org/researchers/puyuan-xing/)

## Paper journal

- [Clinical Cancer Research](https://scholariq.org/journals/clinical-cancer-research/)

## Paper primary topic

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Paper topics

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.